ALL-REMOTE COMPANY/WILMINGTON, Del. / Apr 29, 2024 / Business Wire / Phreesia, Inc. (NYSE: PHR) (“Phreesia”) today announced that it will release its fiscal first quarter 2025 financial results after the close of market trading on Thursday, May 30, 2024. Phreesia will issue a press release announcing its quarterly results and the company’s quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal first quarter results starting at 5PM Eastern Time on the same day.
To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or visit the “Events & Presentations” section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
ABOUT PHREESIA
Phreesia is a trusted leader in patient activation, giving providers, life sciences companies, payers and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.
| Last Trade: | US$16.25 |
| Daily Change: | 0.21 1.31 |
| Daily Volume: | 2,060,188 |
| Market Cap: | US$973.540M |
December 08, 2025 September 04, 2025 September 04, 2025 September 02, 2025 May 28, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load